Dr. Reddy's Laboratories Ltd stock (INE089A01023): modest move as investors eye analyst views and India listing

Dr. Reddy's Laboratories Ltd shares showed only a modest move at the start of June, with the stock trading around INR 1,300 on the National Stock Exchange of India (NSE) on 06/01/2026, according to live data cited by The Economic Times as of 06/01/2026. The Economic Times live blog on 06/01/2026 reported intraday prices around INR 1,293.70 to INR 1,304.80 and highlighted a weekly return of approximately -0.28%, underlining that the recent performance has been slightly negative but far from dramatic for the Indian pharmaceutical group.

The home-market listing in India remains the primary reference point for the company, which is part of the domestic large-cap universe and is widely followed in the country where health-care stocks can be sensitive to regulatory headlines and export dynamics. The Economic Times price feed noted that on 06/01/2026 Dr. Reddy's Laboratories Ltd was down about 0.17% to 0.76% at different intraday snapshots, with the 7-day exponential moving average reported near INR 1,310.93, providing a short-term technical anchor for traders who monitor momentum closely in the Indian market.

As of: 06/01/2026

By the editorial team - specialized in equity coverage.

Dr. Reddy's Laboratories Ltd: core business model

Dr. Reddy's Laboratories Ltd operates as a diversified global pharmaceutical company focused on developing, manufacturing and marketing generic and branded drugs as well as active pharmaceutical ingredients, with sales driven mainly by prescription generics, over-the-counter products and active ingredients supplied to other drug makers.

What banks and research houses say about Dr. Reddy's Laboratories Ltd

For the NYSE-listed American Depositary Shares under the ticker RDY, aggregated data from MarketBeat as of 05/29/2026 indicate that Dr. Reddy's Laboratories carries a consensus "Hold" rating from four Wall Street research analysts. According to MarketBeat, the average 12-month price target for RDY is reported at USD 16.90 as of 05/29/2026, with the highest and lowest targets both at USD 16.90, implying an expected upside of roughly 23.85% from a current reference price of about USD 13.65 as of the same date, although individual investors should be aware that such targets can change when new quarterly results or regulatory updates appear.

MarketBeat also notes that the previous close for the RDY ADRs stood around USD 13.64 on 05/29/2026 before extended-hours trading, which is in line with the modestly subdued recent performance seen in the local Indian listing where the share price hovered in the INR 1,300 range around the beginning of June, according to The Economic Times as of 06/01/2026. The combination of a predominantly neutral analyst stance on Wall Street and a slightly negative weekly return on the NSE suggests that professional observers are currently neither strongly optimistic nor deeply pessimistic, leaving room for future earnings releases, regulatory outcomes, or product pipeline news to shift sentiment in either direction.

Conclusion

The start of June finds Dr. Reddy's Laboratories Ltd trading slightly lower on its home-market NSE listing in India, with weekly returns fractionally negative and intraday prices near INR 1,300 according to The Economic Times on 06/01/2026. At the same time, the NYSE-traded ADRs carry a consensus "Hold" stance and an average USD 16.90 price target as of 05/29/2026 per MarketBeat, indicating that analysts see some potential upside without a strong conviction either way. How the stock trades from here will likely depend on the next set of financial results, regulatory milestones and competitive developments in the global generic and specialty pharmaceutical markets in which Dr. Reddy's Laboratories Ltd is active.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.